Skip to Main Content

Author Details

Denise M Wolf
University of California San Francisco
1998
64
33
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36759733A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF<sup>V600E</sup> colorectal tumors.Nat Cancer2023
38086377Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.Cell Rep Med2023
37794508B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.Breast Cancer Res2023
37738542Characterization of the Tumor Microenvironment of De Novo Oligometastatic Breast Cancer in a Nationwide Cohort.JCO Precis Oncol2023
37188791Development and testing of a polygenic risk score for breast cancer aggressiveness.NPJ Precis Oncol2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
37146605Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.Cancer Cell2023
37029329Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Breast Cancer Res Treat2023
36595917Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors.STAR Protoc2022
35377948Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.Clin Cancer Res2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ Breast Cancer2022
34143979Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.Cancer Cell2021
33767190Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.NPJ Breast Cancer2021
33567262Germline genetic contribution to the immune landscape of cancer.Immunity2021
33648460Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments.BMC Cancer2021
34591612A protein interaction landscape of breast cancer.Science2021
34611148Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.NPJ Breast Cancer2021
34741023Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial.Nat Commun2021
34095775PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial.JAMIA Open2021
31160710Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.Nat Cell Biol2019
30107040Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.Clin Pharmacol Ther2019
31433971The Immune Landscape of Cancer.Immunity2019
31142502Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.Clin Cancer Res2019
29296631Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.J Med Imaging (Bellingham)2018
32914002Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.JCO Precis Oncol2018
29942093A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.Nat Med2018
29617664Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.Cell Rep2018
29659933Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.J Natl Cancer Inst2018
29625055An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.Cell2018
29625048Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.Cell2018
29311117Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).Clin Cancer Res2018
27815749Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.Breast Cancer Res Treat2017
28948212DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.NPJ Breast Cancer2017
28851423The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.Breast Cancer Res2017
28893315Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Breast Cancer Res2017
26921330An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer.Cancer Res2016
27424807Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.Cancer Cell2016
26875185A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies.Breast Cancer Res Treat2016
25432738Expression profiling of circulating tumor cells in metastatic breast cancer.Breast Cancer Res Treat2015
26021444Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response.Breast Cancer Res2015
25712686The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.Clin Cancer Res2015
24516633Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.PLoS One2014
28898680Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity.Cancer Cell2014
25446897Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.Cancer Cell2014
25109877Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.Cell2014
23910573A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.Mol Oncol2013
24205370The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.PLoS One2013
22198468Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Breast Cancer Res Treat2012
22941572Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors.Breast Cancer Res Treat2012
  • 1 - 50 of 64

Recommended Authors

Seyed Ali Madani Tonekaboni
Princess Margaret Cancer Research Centre
Career Start Year 2016
Number of shared co-authors 1
Elana J Fertig
Johns Hopkins University School of Medicine
Career Start Year 2010
Number of shared co-authors 11
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Kahn Rhrissorrakrai
T.J. Watson Research Center
Career Start Year 2008
Number of shared co-authors 5
Eric Paquet
University of Laval
Career Start Year 2007
Number of shared co-authors 1
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 6
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 11
Armand Bankhead
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 2005
Number of shared co-authors 3
Chao Cheng
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 4
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 8
Nathalie Pochet
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 2
Gabriela Alexe
Dana-Farber Cancer Institute
Career Start Year 2004
Number of shared co-authors 6
Christina Curtis
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 20
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2003
Number of shared co-authors 3
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 42
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 9
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 22
Mar??a Rodr??guez Mart??nez
Herbert Irving Cancer Research Center, Columbia University Medical Center
Career Start Year 2002
Number of shared co-authors 2
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 4
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 1
Ludmila Danilova
Bloomberg-Kimmel Immunotherapy Institute, Johns Hopkins University School of Medicine
Career Start Year 2001
Number of shared co-authors 29
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 10
Dana Pe'er
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 5
Benedikt Brors
German Cancer Research Center (DKFZ)
Career Start Year 1997
Number of shared co-authors 6
Ole Christian Lingj??rde
University of Oslo
Career Start Year 1997
Number of shared co-authors 4
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 13
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 2
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 15
Pablo Tamayo
University of California San Diego
Career Start Year 1988
Number of shared co-authors 17
Yuval Kluger
Yale University School of Medicine
Career Start Year 1984
Number of shared co-authors 6

Collaborators

Laura J Van't Veer
University of California San Francisco
Co-authored papers 39
Christina Yau
University of California San Francisco
Co-authored papers 28
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 10
William F Symmans
Co-authored papers 10
Adam P Arkin
Lawrence Berkeley National Laboratory
Co-authored papers 9
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 9
Claudine Isaacs
Co-authored papers 8
Minetta C Liu
Co-authored papers 8
Rita Nanda
Co-authored papers 6
Vesteinn Thorsson
Institute for Systems Biology
Co-authored papers 5
Andrew D Cherniack
Dana-Farber Cancer Institute
Co-authored papers 5
Judy C Boughey
Mayo Clinic
Co-authored papers 5
Scott M Berry
University of Kansas Medical Center
Co-authored papers 4
Joe W Gray
Oregon Health and Science University
Co-authored papers 4
Elad Ziv
Institute for Human Genetics, University of California San Francisco (UCSF)
Co-authored papers 4
Melissa Paoloni
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Lajos Pusztai
Co-authored papers 4
Christopher C Benz
Buck Institute for Research on Aging
Co-authored papers 4
Paul T Spellman
Oregon Health & Science University Hospital.
Co-authored papers 3
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Co-authored papers 3
Teresa Helsten
Moores Cancer Center, University of California San Diego
Co-authored papers 3
Rehan Akbani
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Co-authored papers 3
Peter W Laird
Van Andel Institute
Co-authored papers 3
James E Korkola
Co-authored papers 3
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 3
Jianfang Liu
Peking University Third Hospital
Co-authored papers 3
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 3
Rachel L Yung
University of Washington
Co-authored papers 3
Release 1.2